AstraZeneca PLC (LON:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

AstraZeneca PLC (LON:AZN) has received an average recommendation of “Moderate Buy” from the nine research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is £104.12 ($131.75).

A number of equities analysts have recently issued reports on the stock. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. JPMorgan Chase & Co. reiterated an “overweight” rating and set a £140 ($177.15) target price on shares of AstraZeneca in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a £110 ($139.19) target price on shares of AstraZeneca in a research note on Tuesday, September 3rd. Finally, Berenberg Bank reissued a “buy” rating and set a £150 ($189.80) price target on shares of AstraZeneca in a research report on Monday, September 2nd.

Insider Buying and Selling

In other news, insider Tony Mok bought 1,500 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of £126.80 ($160.45) per share, with a total value of £190,200 ($240,668.10). Also, insider Pascal Soriot bought 20,000 shares of AstraZeneca stock in a transaction dated Thursday, November 14th. The stock was acquired at an average cost of £102.03 ($129.10) per share, with a total value of £2,040,600 ($2,582,057.45). In the last three months, insiders have acquired 23,500 shares of company stock valued at $223,316,000. 0.04% of the stock is owned by insiders.

AstraZeneca Stock Down 0.4 %

Shares of LON AZN opened at GBX 9,925 ($125.59) on Friday. AstraZeneca has a 12-month low of GBX 9,461 ($119.71) and a 12-month high of £133.88 ($169.40). The firm’s 50-day simple moving average is £114.45 and its 200 day simple moving average is £120.91. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The company has a market cap of £153.84 billion, a price-to-earnings ratio of 3,164.76, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.